Peripheral 5-HT upregulates hepatic FGF21 expression and plasma FGF21 levels, leading to metabolic diseases such as obesity, insulin resistance, type 2 diabetes, and NAFLD. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.